Archives
RCT | Sotorasib vs. docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation
20 Mar, 2023 | 13:10h | UTCSotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
Docetaxel is the recommended treatment for non-small-cell lung cancer (NSCLC) at disease progression, but it has shown modest clinical benefit.
The CodeBreaK 200 trial compares the KRAS inhibitor sotorasib with docetaxel in patients with advanced NSCLC.https://t.co/Sk7Rk1lAl2
— The Lancet (@TheLancet) March 9, 2023
Review | Neurogenic shock: definition, identification, and management in the ED
20 Mar, 2023 | 13:09h | UTCNeurogenic Shock: Definition, Identification, and Management in the ED – emDocs
AHA Scientific Statement | Evaluation and management of pulmonary hypertension in noncardiac surgery
17 Mar, 2023 | 13:12h | UTCTop Things to Know: Evaluation and Management of Pulmonary HTN in Non-Cardiac Surgery – American Heart Association
Cohort Study | COVID-19 outpatients mostly at low risk for VTE, but age, being male, and obesity are risk factors
17 Mar, 2023 | 13:11h | UTCSummary: The article discusses a cohort study that aimed to assess the risk of venous thromboembolism (VTE) among outpatients with COVID-19 and identify independent predictors of VTE.
The study used data from two integrated healthcare delivery systems in California and included 398.530 nonhospitalized adults aged 18 years or older with COVID-19 diagnosed between January 1, 2020, and January 31, 2021, with follow-up through February 28, 2021.
The results showed that the overall risk of VTE among outpatients with COVID-19 is low, but higher in the first 30 days after diagnosis. Factors associated with a higher risk of VTE in COVID-19 outpatients included:
- Age 55 years or older.
- Being male.
- history of VTE or thrombophilia.
- Body mass index greater than or equal to 30.0.
The study’s results could inform future randomized trials to explore targeted VTE preventive strategies and more intensive short-term surveillance for patients with COVID-19 who are at a higher risk of developing VTE.
Commentary: Venous blood clots rare among COVID-19 outpatients, study finds – CIDRAP
Commentary on Twitter
The rate of VTE was low in outpatients with #COVID19 in the first 30 days, and even lower >30 days. Factors associated with a higher risk of VTE in included age ≥55, male, prior VTE/thrombophilia, and BMI ≥30. https://t.co/3hwfDW88k4
— JAMA Network Open (@JAMANetworkOpen) March 13, 2023
Guidelines for the management of patients with substance intoxication presenting to the ED
17 Mar, 2023 | 13:09h | UTC
ESGE Position Statement | Curriculum for bariatric endoscopy and endoscopic treatment of the complications of bariatric surgery
17 Mar, 2023 | 13:06h | UTC
Consensus Statement | Point-of-care ultrasound for systematic assessment of the crashing neonate
17 Mar, 2023 | 13:05h | UTC
Consensus Paper | The management of developmental dysplasia of the hip in children aged under three months
17 Mar, 2023 | 13:07h | UTCRelated Guideline: Detection and Nonoperative Management of Pediatric Developmental Dysplasia of the Hip in Infants Up to Six Months of Age – American Academy of Orthopaedic Surgeons
Post-hoc analysis | Could SGLT2 inhibitors have a beneficial effect on gout symptoms?
17 Mar, 2023 | 13:02h | UTCRelated: Post-hoc analysis | Can SGLT2 inhibitors reduce the risk of hyperuricemia and gout?
Associations of relative fat mass, a new index of adiposity, with type-2 diabetes in the general population
17 Mar, 2023 | 13:04h | UTC
RCT | Adjunctive Cariprazine for the treatment of patients with major depressive disorder
17 Mar, 2023 | 13:01h | UTCAdjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study – American Journal of Psychiatry (link to abstract – $ for full-text)
Commentary on Twitter
RCT: Adjunctive cariprazine (1.5 mg/d) demonstrated efficacy in reducing depressive symptoms in adults with MDD and inadequate response to ADs vs. placebo at week 6 (−14.1 vs. −11.5) https://t.co/k4QST25FeF
— P𝘧OL (@psychopharmacol) March 3, 2023
Review | Cardiac rehabilitation for heart failure: ‘Cinderella’ or evidence-based pillar of care?
17 Mar, 2023 | 13:00h | UTC
Review | Evidence-based informed consent form for total knee arthroplasty
17 Mar, 2023 | 12:58h | UTC
SR | Splinting for carpal tunnel syndrome
17 Mar, 2023 | 12:57h | UTCSplinting for carpal tunnel syndrome – Cochrane Library
Summary: Splinting for carpal tunnel syndrome – Cochrane Library
Cohort Study | Leukotriene-receptor antagonist use during pregnancy not linked to neuropsychiatric events in offspring
17 Mar, 2023 | 12:56h | UTCCommentary: In utero exposure to asthma medication not tied to risks of neurodevelopmental disorders – MDedge
M-A | Has the therapeutical ceiling been reached in Crohn’s disease randomized controlled trials?
17 Mar, 2023 | 12:55h | UTC
M-A | Health effects of the time-restricted eating in adults with obesity
17 Mar, 2023 | 12:54h | UTCRelated:
Time-Restricted Eating: Integrating The What With The When – Advances in Nutrition
SR | Planned hospital birth compared with planned home birth for pregnant women at low risk of complications
17 Mar, 2023 | 12:51h | UTCSummary: Planned hospital birth versus planned home birth – Cochrane Library
Methods Primer | Non-linear predictor outcome associations
17 Mar, 2023 | 12:52h | UTCNon-linear predictor outcome associations – BMJ Medicine
M-A | Prevalence of perinatal depression in low- and middle-income countries
17 Mar, 2023 | 12:49h | UTC
Commentary on Twitter
Depression amongst women, during pregnancy and up to a year postpartum, in low- and middle-income countries is common. Urgent action is required improve health outcomes for women and babies. https://t.co/xMSiqaOmiu @PerinatalEpi @mercyperinatal @UniMelb
— JAMA Psychiatry (@JAMAPsych) March 8, 2023
Cohort Study | Timing of antidepressant discontinuation during pregnancy and postpartum psychiatric outcomes
17 Mar, 2023 | 12:48h | UTC
Commentary on Twitter
A population-based study of 57,934 pregnant women in Denmark and Norway found that women who were previously stable antidepressant users but discontinued treatment late in pregnancy presented an elevated probability of postpartum initiating psycholeptics. https://t.co/k42OhXwgfi
— JAMA Psychiatry (@JAMAPsych) March 9, 2023
Review | Pathophysiological gaps, diagnostic challenges, and uncertainties in cardiac sarcoidosis
17 Mar, 2023 | 12:47h | UTC
Review | Transcatheter interventions for heart failure
17 Mar, 2023 | 12:44h | UTCTranscatheter interventions for heart failure – EuroIntervention
Study shows increased nuchal translucency can be ascertained using transverse planes
17 Mar, 2023 | 12:45h | UTC
Commentary on Twitter
Increased nuchal translucency can be ascertained using transverse planes https://t.co/WB2o7JvPug pic.twitter.com/yumS5sfvsN
— AJOG (@AJOG_thegray) December 2, 2022
FDA issues new information on cases of squamous cell carcinoma and lymphomas around breast implants
16 Mar, 2023 | 13:28h | UTCSummary: The US Food and Drug Administration (FDA) has provided an update on reports of squamous cell carcinoma (SCC) in the scar tissue (capsule) that forms around breast implants. The FDA is aware of 19 cases of SCC in the capsule around the breast implant from published literature, including 3 reports of deaths from the disease.
While the FDA continues to believe that occurrences of SCC in the capsule around the breast implant may be rare, the cause, incidence, and risk factors remain unknown. Health care providers and people who have or are considering breast implants should be aware that cases of SCC and various lymphomas in the capsule around the breast implant have been reported to the FDA and in the literature.
The FDA continues to ask health care providers and people with breast implants to report cases of SCC, lymphomas, or any other cancers around breast implants.
FDA Safety Communication: Reports of Squamous Cell Carcinoma (SCC) in the Capsule Around Breast Implants – FDA Safety Communication – U.S. Food & Drug Administration
Related:
FDA Report: 660 Cases of Breast Implant-Associated Anaplastic Large Cell Lymphoma
Study: Long-term Outcomes of Silicone Breast Implants